DENTSPLY SIRONA (NASDAQ:XRAY) Price Target Cut to $12.00 by Analysts at JPMorgan Chase & Co.

DENTSPLY SIRONA (NASDAQ:XRAY) had its price objective decreased by equities research analysts at JPMorgan Chase & Co. from $14.00 to $12.00 in a report issued on Friday,Benzinga reports. The brokerage presently has a “neutral” rating on the medical instruments supplier’s stock. JPMorgan Chase & Co.‘s price objective suggests a potential upside of 7.33% from the company’s previous close.

Several other research analysts have also issued reports on XRAY. Weiss Ratings restated a “sell (d-)” rating on shares of DENTSPLY SIRONA in a research report on Wednesday, October 8th. Barrington Research reaffirmed an “outperform” rating and set a $18.00 target price on shares of DENTSPLY SIRONA in a research report on Wednesday, October 29th. Needham & Company LLC reiterated a “hold” rating on shares of DENTSPLY SIRONA in a research note on Friday, September 26th. Wall Street Zen lowered shares of DENTSPLY SIRONA from a “buy” rating to a “hold” rating in a research report on Saturday, October 18th. Finally, Wells Fargo & Company decreased their price target on shares of DENTSPLY SIRONA from $15.00 to $12.00 and set an “equal weight” rating for the company in a report on Friday. Two equities research analysts have rated the stock with a Buy rating, ten have issued a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average target price of $16.42.

DENTSPLY SIRONA Stock Performance

Shares of DENTSPLY SIRONA stock traded up $0.16 during trading hours on Friday, reaching $11.18. The company’s stock had a trading volume of 5,992,631 shares, compared to its average volume of 3,061,266. The stock has a market cap of $2.23 billion, a P/E ratio of -2.36, a price-to-earnings-growth ratio of 0.81 and a beta of 1.00. DENTSPLY SIRONA has a one year low of $10.69 and a one year high of $20.59. The company has a debt-to-equity ratio of 1.13, a quick ratio of 1.11 and a current ratio of 1.69. The company’s 50 day simple moving average is $13.04 and its 200 day simple moving average is $14.48.

DENTSPLY SIRONA (NASDAQ:XRAY) last announced its quarterly earnings results on Thursday, November 6th. The medical instruments supplier reported $0.37 EPS for the quarter, missing the consensus estimate of $0.45 by ($0.08). DENTSPLY SIRONA had a negative net margin of 25.85% and a positive return on equity of 16.33%. The firm had revenue of $904.00 million during the quarter, compared to analyst estimates of $900.33 million. During the same quarter in the previous year, the business posted $0.50 EPS. DENTSPLY SIRONA’s revenue for the quarter was down 4.9% compared to the same quarter last year. DENTSPLY SIRONA has set its FY 2025 guidance at 1.600-1.600 EPS. As a group, analysts expect that DENTSPLY SIRONA will post 1.84 EPS for the current fiscal year.

Institutional Trading of DENTSPLY SIRONA

A number of large investors have recently bought and sold shares of the stock. Vanguard Group Inc. raised its stake in DENTSPLY SIRONA by 4.1% during the third quarter. Vanguard Group Inc. now owns 22,006,576 shares of the medical instruments supplier’s stock worth $279,263,000 after acquiring an additional 869,566 shares in the last quarter. Price T Rowe Associates Inc. MD grew its holdings in shares of DENTSPLY SIRONA by 11.3% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 13,961,759 shares of the medical instruments supplier’s stock worth $208,590,000 after purchasing an additional 1,412,517 shares during the last quarter. AQR Capital Management LLC grew its holdings in shares of DENTSPLY SIRONA by 109.8% in the 2nd quarter. AQR Capital Management LLC now owns 13,316,771 shares of the medical instruments supplier’s stock worth $211,470,000 after purchasing an additional 6,970,086 shares during the last quarter. Fuller & Thaler Asset Management Inc. increased its position in shares of DENTSPLY SIRONA by 4.7% during the 1st quarter. Fuller & Thaler Asset Management Inc. now owns 12,077,949 shares of the medical instruments supplier’s stock worth $180,445,000 after purchasing an additional 538,531 shares in the last quarter. Finally, Lazard Asset Management LLC lifted its holdings in DENTSPLY SIRONA by 8.0% during the 2nd quarter. Lazard Asset Management LLC now owns 10,107,657 shares of the medical instruments supplier’s stock valued at $160,508,000 after purchasing an additional 745,421 shares during the last quarter. 95.70% of the stock is currently owned by institutional investors.

DENTSPLY SIRONA Company Profile

DENTSPLY SIRONA Inc manufactures and sells various dental products and technologies worldwide. It operates in four segments: Connected Technology Solutions, Essential Dental Solutions, Orthodontic and Implant Solutions, and Wellspect Healthcare. The company offers dental equipment comprising imaging equipment, motorized dental handpieces, treatment centers, other instruments, amalgamators, mixing machines, and porcelain furnaces; and dental CAD/CAM technologies to support dental restorations, such as intraoral scanners, 3-D printers, mills, other software and services, and a full-chairside economical restoration of esthetic ceramic dentistry, as well as DS Core, its cloud-based platform.